Table 4.

Main meaningful outcome comparison in included reviews.

Author (y)	Type of patients	Intervention	Outcome(s)
			OS	DFS	RFS	TRM	RR	Survival from relapse	Death rate	Relapse or death rate
Li (2019) [27]	Patients with intermediate-risk AML in CR1	Allo-SCT	HR = 0.84(0.73–0.97)		HR = 0.82(0.73–0.92)	HR = 4.16(3.37–5.15)	HR = 0.53(0.42–0.66)
Li (2015) [26]	Patients with intermediate-risk AML in CR1	Allo-SCT	HR = 0.43(0.22–0.84)		HR = 0.68(0.48–0.95)	HR = 3.09(1.38–6.92)	HR = 0.58(0.45–0.75)
Ma (2015) [25]	FLT3/ITD AML patients	Allo-SCT	OR = 2.88(2.04–4.05)	OR = 2.84(1.89–4.25)			OR = 0.09(0.05–0.18)
Koreth (2009) [31]	AML patients in CR1	Allo-SCT	HR = 0.90(0.82–0.97)		HR = 0.80(0.74–0.86)
Jing (2010) [29]	AML patients in CR1	Allo-SCT	HR = 1.05(0.91–1.21)	HR = 0.89(0.80–0.98)		RR = 1.90(1.34–2.70)	RR = 0.79(0.72–0.87)	HR = 2.09(1.41–3.08)
Koreth (2009) [31]	AML patients in CR1	Allo-SCT	HR = 0.90(0.82–0.97)		HR = 0.80(0.74–0.86)
Levi (2004) [34]	AML patients in CR1	ABMT							RR = 0.94(0.84–1.09)	RR = 0.85(0.75–0.97)
Nathan (2004) [33]	Adult patients with AML	ABMT	1.01(0.89–1.15)	1.24(1.06–1.44)		OR = 2.63(1.60–4.32)
Levi (2004) [34]	AML patients in CR1	ABMT						RR = 0.94(0.84–1.09)	RR = 0.85(0.75–0.97)